Avalo Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AVTX Nasdaq 8731 https://www.avalotx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avalo Therapeutics Inc

Avalo Reports 2022 Financial Results and Provides Business Updates - Mar 29th, 2023 11:30 am
Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference - Mar 7th, 2023 12:00 pm
Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants - Feb 3rd, 2023 2:54 am
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants - Feb 2nd, 2023 9:01 pm
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma - Jan 17th, 2023 12:00 pm
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates - Nov 7th, 2022 12:30 pm
Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million - Nov 7th, 2022 12:00 pm
Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage - Sep 6th, 2022 11:00 am
Avalo to Present at the H.C. Wainwright Global Investment Conference - Sep 1st, 2022 11:00 am
Avalo Therapeutics Announces Board Changes - Aug 11th, 2022 8:01 pm
These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer - Aug 9th, 2022 2:39 pm
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates - Aug 4th, 2022 11:30 am
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II) - Aug 2nd, 2022 11:30 am
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics - Aug 1st, 2022 11:00 am
Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split - Jul 6th, 2022 8:05 pm
Investors in Avalo Therapeutics (NASDAQ:AVTX) have unfortunately lost 90% over the last three years - Jun 20th, 2022 4:10 pm
Avalo to Present at the 2022 Jefferies Healthcare Conference - Jun 2nd, 2022 11:30 am
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA) - May 18th, 2022 11:30 am
Avalo to Present at the H.C. Wainwright Global Life Sciences Conference - May 17th, 2022 11:30 am
Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates - May 5th, 2022 11:30 am